ALFA Finder| Revenue growth | 35.3% YoY in Q4; 28.2% YoY for full FY26. |
|---|---|
| Margins | Matured units at 29% EBITDA; group margin diluted to 21.1% by new units. |
| Demand visibility | Strong; IP volumes grew 17.9% YoY in Q4 FY26. |
| Management confidence | Confident in 10-12% EBITDA growth for Telangana cluster and new unit ramp-ups. |
Growth
FY26 revenue up 28.2% to INR 3,931cr; PAT declined to INR 242cr due to expansion costs and EBITDA erosion.
Outlook
Planned INR 1,500cr QIP to retire INR 1,000cr debt and fund greenfield projects in Karnataka, Kerala, and Tamil Nadu.
Risks
Delays in insurance empanelment for new hospitals; ongoing impact from Gulf War and domestic austerity measures.
Earnings Call filed with BSE, NSE: KIMS. Summary written with AI assistance from the document.
Krishna Institute of Medical Sciences Ltd: key numbers
- Share price
- ₹722.00
- Market cap
- ₹30,324 Cr
- Revenue (annual)
- ₹3,905 Cr
- Net profit (annual)
- ₹241.4 Cr
- P/E (TTM)
- 142.8×Sector 54.5×
- Promoter holding
- 32.66%+0.16% QoQ
- FII holding
- 15.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krishna Institute of Medical Sciences Ltd
All →Krishna Institute of Medical Sciences Earnings Call Transcript: Key Takeaways
KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.
Krishna Institute of Medical Sciences Other Announcement
KIMS's CARE Ratings monitoring report shows ₹1,311.81 crore of the ₹1,476.45 crore QIP proceeds utilised till Q2 FY27. No deviation from the stated objects was reported.
Krishna Institute of Medical Sciences Management Change
KIMS re-appointed Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as CMD, and Ms. Dandamudi Anitha as Whole-time Director. Terms start in 2027.
- Execution
- 5 years
Krishna Institute of Medical Sciences Investor Presentation: Key Takeaways
Q2 FY27 total revenue Rs13,630 Mn (+41.3% YoY), EBITDA Rs2,789 Mn (20.5% margin), PAT Rs757 Mn (+5.1% YoY). Expansion via 700+ beds planned.
Krishna Institute of Medical Sciences Results Update
KIMS reported Q2 FY27 consolidated revenue of Rs 1,363 Crore, up 41.3% YoY, with PAT of Rs 76 Crore. EBITDA rose 34% YoY to Rs 279 Crore.
Krishna Institute of Medical Sciences Q2 FY27 Results: Net Profit ₹74.6 Cr, Up 3.6% YoY
Krishna Institute of Medical Sciences Ltd reported revenue from operations of ₹1,344 Cr (+39.9% YoY) and net profit of ₹74.6 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹74.6 Cr · +3.6% YoY